AP4 is required for mitogen- and c-MYC-induced cell cycle progression

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7316-7327

  Jackstadt, Rene ^a   Hermeking, Heiko ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

AP 4; AP4; c MYC; Cell cycle; Cytokinesis; TFAP4

Indexed keywords

AP4 ESTROGEN RECEPTOR FUSION PROTEIN; AP4 PROTEIN; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; CYCLIN DEPENDENT KINASE 2; ESTROGEN RECEPTOR; HYBRID PROTEIN; MYC PROTEIN; UNCLASSIFIED DRUG; MITOGENIC AGENT; REPIN1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP4, MOUSE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINESIS; DNA DAMAGE; EMBRYO; FIBROBLAST; HUMAN; HUMAN CELL; MITOGENESIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TETRAPLOIDY; ANIMAL; C57BL MOUSE; CELL CYCLE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CYTOLOGY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYCLIN-DEPENDENT KINASE 2; FIBROBLASTS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; MITOGENS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS;

EID: 84907482159     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2348     Document Type: Article

References (37)

1. Atchley WR and Fitch WM. A natural classification of the basic helix-loop-helix class of transcription factors. Proc Natl Acad Sci U S A. 1997; 94(10):5172-5176.
2. Mermod N, Williams TJ and Tjian R. Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature. 1988; 332(6164):557-561.
3. Imai K and Okamoto T. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem. 2006; 281(18):12495-12505.
4. Kim MY, Jeong BC, Lee JH, Kee HJ, Kook H, Kim NS, Kim YH, Kim JK, Ahn KY and Kim KK. A repressor complex, AP4 transcription factor and geminin, negatively regulates expression of target genes in nonneuronal cells. Proc Natl Acad Sci U S A. 2006; 103(35):13074-13079.
5. Tsujimoto K, Ono T, Sato M, Nishida T, Oguma T and Tadakuma T. Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis. J Biol Chem. 2005; 280(30):27638-27644.
6. Hu YF, Luscher B, Admon A, Mermod N and Tjian R. Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev. 1990; 4(10):1741-1752.
7. Jackstadt R, Roh S, Neumann J, Jung P, Hoffmann R, Horst D, Berens C, Bornkamm GW, Kirchner T, Menssen A and Hermeking H. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. The Journal of experimental medicine. 2013; 210(7):1331-1350.
8. Jung P, Menssen A, Mayr D and Hermeking H. AP4 encodes a c-MYC-inducible repressor of p21. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(39):15046-15051.
9. Jung P and Hermeking H. The c-MYC-AP4-p21 cascade. Cell cycle. 2009; 8(7):982-989.
10. Jackstadt R, Jung P and Hermeking H. AP4 directly downregulates p16 and p21 to suppress senescence and mediate transformation. Cell death & disease. 2013; 4:e775.
11. Hu BS, Zhao G, Yu HF, Chen K, Dong JH and Tan JW. High expression of AP-4 predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. Tumour Biol. 2012; 34(1):271-6.
12. Xinghua L, Bo Z, Yan G, Lei W, Changyao W, Qi L, Lin Y, Kaixiong T, Guobin W and Jianying C. The overexpression of AP-4 as a prognostic indicator for gastric carcinoma. Med Oncol. 2012; 29(2):871-877.
13. Shi L, Jackstadt R, Siemens H, Li H, Kirchner T and Hermeking H. p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res. 2014; 74(2):532-542.
14. D'Annibale S, Kim J, Magliozzi R, Low TY, Mohammed S, Heck AJ and Guardavaccaro D. Proteasome-dependent Degradation of Transcription Factor Activating Enhancer-binding Protein 4 (TFAP4) Controls Mitotic Division. J Biol Chem. 2014; 289(11):7730-7737.
15. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC and Li F. The c-Myc target gene network. Semin Cancer Biol. 2006; 16(4):253-264.
16. Adhikary S and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005; 6(8):635-645.
17. Alexandrow MG, Kawabata M, Aakre M and Moses HL. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc Natl Acad Sci U S A. 1995; 92(8):3239-3243.
18. Meyer N, Kim SS and Penn LZ. The Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol. 2006; 16(4):275-287.
19. Berns K, Hijmans EM, Koh E, Daley GQ and Bernards R. A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts. Oncogene. 2000; 19(29):3330-3334.
20. Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, Alitalo K and Eilers M. Repression of cyclin D1: a novel function of MYC. Mol Cell Biol. 1994; 14(6):4032-4043.
21. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J and Eilers M. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999; 18(19):5321-5333.
22. Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, O'Connell BC, Mateyak MK, Tam W, Kohlhuber F, Dang CV, Sedivy JM, Eick D, Vogelstein B and Kinzler KW. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A. 2000; 97(5):2229-2234.
23. Galaktionov K, Chen X and Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature. 1996; 382(6591):511-517.
24. Menssen A, Epanchintsev A, Lodygin D, Rezaei N, Jung P, Verdoodt B, Diebold J and Hermeking H. c-MYC Delays Prometaphase by Direct Transactivation of MAD2 and BubR1: Identification of Mechanisms Underlying c-MYC-Induced DNA Damage and Chromosomal Instability. Cell Cycle. 2007; 6(3):339-352.
25. Felsher DW, Zetterberg A, Zhu J, Tlsty T and Bishop JM. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc Natl Acad Sci U S A. 2000; 97(19):10544-10548.
26. Brooks EE, Gray NS, Joly A, Kerwar SS, Lum R, Mackman RL, Norman TC, Rosete J, Rowe M, Schow SR, Schultz PG, Wang X, Wick MM and Shiffman D. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem. 1997; 272(46):29207-29211.
27. Ewald B, Sampath D and Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther. 2007; 6(4):1239-1248.
28. Berthet C, Aleem E, Coppola V, Tessarollo L and Kaldis P. Cdk2 knockout mice are viable. Curr Biol. 2003; 13(20):1775-1785.
29. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbero JL, Malumbres M and Barbacid M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet. 2003; 35(1):25-31.
30. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP and Barbacid M. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet. 1999; 22(1):44-52.
31. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A and Kiyokawa H. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol. 1999; 19(10):7011-7019.
32. Normand G and King RW. Understanding cytokinesis failure. Adv Exp Med Biol. 2010; 676:27-55.
33. Adon AM, Zeng X, Harrison MK, Sannem S, Kiyokawa H, Kaldis P and Saavedra HI. Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells. Mol Cell Biol. 2010; 30(3):694-710.
34. Doxsey S. Duplicating dangerously: linking centrosome duplication and aneuploidy. Mol Cell. 2002; 10(3):439-440.
35. Fukasawa K. Centrosome amplification, chromosome instability and cancer development. Cancer Lett. 2005; 230(1):6-19.
36. McDermott KM, Zhang J, Holst CR, Kozakiewicz BK, Singla V and Tlsty TD. p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS biology. 2006; 4(3):e51.
37. Frank SR, Schroeder M, Fernandez P, Taubert S and Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 2001; 15(16):2069-2082.